Fusion Antibodies, pre-clinical antibody discovery and development experts, and BioTickle, their exclusive distributor in India, are collaborating to provide Indian biopharmaceutical organisations with access to invaluable unique biopharmaceutical development capabilities.
As Dr Richard Jones, CEO of Fusion Antibodies, explained: “We are proud of the support we can offer to the biotherapeutic developers in India who are working at the leading-edge of this global industry. Together with our clients, we are developing novel therapeutic candidates aimed at a range of diseases. We can also support organisations with the development of antibodies that are specifically engineered to neutralise the SARS-CoV-2 virus, which of course is one of the biggest challenges facing the world at the moment.”
Since the emergence of COVID-19, Fusion Antibodies has dedicated resources into developing a panel of unique protein antigens for use in discovery platforms. To date, the proteins have shown excellent profiles in terms of activity and scalability. Furthermore, the company has been awarded a grant from Invest Northern Ireland to expand their COVID-19 focused research to accelerate the discovery of novel therapeutic and diagnostic antibodies.
Dr Richard Jones said:
“Through BioTickle, Fusion Antibodies is well-placed to provide world-class support to Indian biopharmaceutical developers no matter their target therapeutic area, from infectious diseases to oncology.
“Since 2001, we have been dedicated to the discovery and development of antibodies to help bring about a positive change in the healthcare industry. Our team of experts has guided hundreds of projects through critical preclinical stages, and many of our client’s projects have advanced to clinical stage trials.
“Preparing for the future is also at the forefront of Fusion Antibodies. To this, we continue to grow and invest in our technologies and team to ensure we can provide our customers with the support they will need as the industry evolves over the next 10 to 20 years.”
News & Analysis